Summary Articles on Hep C from EASL

[Guest guest]

HIVandHepatitis.com

Monoclonal Antibody Bavituximab Well-Tolerated by HIV/HCV Coinfected People

SUMMARY

An experimental monoclonal antibody that inhibits HCV replication was safe and

well-tolerated in a clinical trial of HIV positive people coinfected with

chronic hepatitis C, researchers reported at EASL 2011.

Once-Daily BI201335 Ups Response to Interferon for Hepatitis C

SUMMARY

Boerhinger Ingelheim's experimental HCV protease inhibitor BI201335 added to

pegylated interferon and ribavirin improved sustained response rates for both

treatment-naive and treatment-experienced genotype 1 patients, researchers

reported at EASL 2011.

[Guest guest]

HIVandHepatitis.com

Monoclonal Antibody Bavituximab Well-Tolerated by HIV/HCV Coinfected People

SUMMARY

An experimental monoclonal antibody that inhibits HCV replication was safe and

well-tolerated in a clinical trial of HIV positive people coinfected with

chronic hepatitis C, researchers reported at EASL 2011.

Once-Daily BI201335 Ups Response to Interferon for Hepatitis C

SUMMARY

Boerhinger Ingelheim's experimental HCV protease inhibitor BI201335 added to

pegylated interferon and ribavirin improved sustained response rates for both

treatment-naive and treatment-experienced genotype 1 patients, researchers

reported at EASL 2011.